Transdermal patches are a type of drug delivery where a pre-prescribed amount of medication is applied as an adhesive patch to the skin and absorbed into the circulation. Pharmaceuticals are delivered through a process referred to as “transdermal.” These patches can be mechanical or electrical and can be used for short- or long-term administration. Transdermal patches stick to the skin and distribute medications. They deliver a precise, preset amount of medication that is absorbed into the blood through the skin. Skin patches provide a number of benefits over oral versions, yet being equally effective as oral-dosage forms. They offer a non-intrusive, painless means of administering medication.
The market for transdermal skin patches was estimated at Us$ 7,695.0 million in 2021, and it is expected that it will expand at a CAGR of 5.0% from 2022 to 2028 attending US$ 10,839.7 million.
In terms of volume, North America owned the majority of the transdermal skin patch market worldwide in 2020, with a 42.4% share, followed by Europe and the Asia Pacific.
Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/5085
The transdermal Neupro patch (Rotigotine), a popular treatment for Parkinson’s disease, will be available in generic form starting in June 2020, according to Vektor Pharma.
The introduction of Rivastigmine Tapes (transdermal patches) for the treatment of Alzheimer’s disease in Japan was announced by Hisamitsu Pharmaceuticals in January 2018.
For its transdermal rotigotine patch, which is NEUPRO, UCB was granted an Import Drug License (IDL) by the China Food and Drug Administration in July 2018. (CFDA).
During the projected period, the worldwide market for transdermal skin patches is anticipated to rise at a faster rate due to the increasing popularity of these patches. Agile Therapeutics, Inc. announced the commercial introduction of Twirla (levonorgestrel and Ethinyl estradiol), a novel irregular, without invasion contraceptive patch, in the United States in December 2020. For women with a BMI of 30 kg/m2, who are of reproductive potential, it is currently accessible in the US through prescription. It is intended to be worn on the upper chest, buttocks, or abdomen (excluding breasts).
Over the course of the projected period, increasing financing and expenditures in medication research are anticipated to drive market expansion for transdermal skin patches. For instance, in May 2019, Mercia invested £2.0 million in Medherant Limited, a leader in transdermal medicine delivery. With this most recent funding, Medherant will be able to decide which three TEPI Patch candidates to forward into clinical testing. Patients all throughout the world will profit significantly from the development of patch products.
The worldwide transdermal skin patch market is anticipated to experience growing challenges due to the skin’s limited capacity to absorb a variety of active chemicals. The stratum corneum serves as the primary barrier to drug permeability and, as a result, restricts the therapeutic bioavailability of the bioactive when using the transdermal drug delivery method, which uses the skin as the effective route for drug administration.
The worldwide market for transdermal skin patches is anticipated to experience growth challenges due to medication failure and transdermal drug delivery system recalls. According to the U.S. Food and Drug Administration, Teva Pharmaceuticals USA recalled a single lot of clonidine transdermal patches in November 2021 because it did not adhere to impurities/degradation criteria (FDA).
A voluntary recall of two batches of Fentanyl Transdermal System 12 mcg/h has been initiated by Alvogen, Inc.
Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/5085
For companies in the worldwide transdermal skin patch market, technological advancements in transdermal medication delivery systems are anticipated to provide attractive development prospects. For instance, ImQuest Biosciences announced the introduction of an antiviral transdermal administration patch in September 2021. Antiretroviral medications will be delivered using the patch. Antiretroviral medications are frequently used to treat HIV infection.
Players in the global transdermal skin patch market can benefit from attractive development possibilities due to the rising prevalence of chronic illnesses worldwide. For instance, the World Health Organization (WHO) claims that the main causes of mortality and disability globally are chronic illnesses including diabetes, cancer, and heart disease.
Market Trends/Key Takeaways:
The global market for transdermal skin patches is anticipated to increase as a result of frequent approvals and launches of new products. For instance, the National Medical Products Administration in China authorised Luye Pharma Group’s Rivastigmine Transdermal Patch in June 2020. For the treatment of mild to severe Alzheimer’s disease, transdermal patches are recommended.
The launch of innovative products by industry players is anticipated to fuel the expansion of the transdermal skin patch market globally. In March 2019, Amneal Pharmaceuticals, Inc. announced the availability of the generic forms of Exelon Patch (Rivastigmine Transdermal System), in doses of 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours.
Includes Samyang Biopharmaceuticals Corp., Teva Pharmaceutical Industries Ltd, Henan Lingrui Pharmaceutical Ltd, Novartis AG, Purdue Pharma Manufacturing LP, Teikoku Pharma USA Inc., Luye Pharma Group, Mylan NV, and 3M Company.
Table of Content:
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Transdermal Skin Patches Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Transdermal Skin Patches Industry Impact
Chapter 2 Global Transdermal Skin Patches Competition by Types, Applications, and Top Regions and Countries
2.1 Global Transdermal Skin Patches (Volume and Value) by Type
2.3 Global Transdermal Skin Patches (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Transdermal Skin Patches Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Transdermal Skin Patches Market Analysis
Chapter 6 East Asia Transdermal Skin Patches Market Analysis
Chapter 7 Europe Transdermal Skin Patches Market Analysis
Chapter 8 South Asia Transdermal Skin Patches Market Analysis
Chapter 9 Southeast Asia Transdermal Skin Patches Market Analysis
Chapter 10 Middle East Transdermal Skin Patches Market Analysis
Chapter 11 Africa Transdermal Skin Patches Market Analysis
Chapter 12 Oceania Transdermal Skin Patches Market Analysis
Chapter 13 South America Transdermal Skin Patches Market Analysis
Chapter 14 Company Profiles and Key Figures in Transdermal Skin Patches Business
Chapter 15 Global Transdermal Skin Patches Market Forecast (2022-2028)
Chapter 16 Conclusions
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/5085
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027